New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2012
13:51 EDTOREX, ARNA, VVUSVIVUS drug's CV profile viewed positively by FDA, says Rodman & Renshaw
After attending an FDA panel hearing focused on the effects of anti-obesity drugs on cardiovascular systems, Rodman & Renshaw believes that the FDA and the panel are comfortable with the cardiovascular profile of VIVUS' drug, Qnexa. The firm indicates that it doesn't expect the agency to require additional cardiovascular tests before Qnexa is approved, and it reiterates an Outperform rating on VIVUS.
News For VVUS;ARNA;OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 27, 2015
17:49 EDTOREXZosano Pharma elects Orexigen's Joseph Hagan to board of directors
Zosano Pharma (ZSAN) announced earlier the election of Joseph Hagan to its board of directors, effective May 22. Hagan is EVP, Chief Business & Financial Officer of Orexigen Therapeutics (OREX). Bruce Steel, chairman of Zosano, remarked that Hagan is "a seasoned business and financial executive with a significant track record in complex partnerships and transactions who will add additional breadth of perspective to our board as Zosano advances its clinical development programs in osteoporosis, hypoglycemia and migraine."
May 21, 2015
10:12 EDTOREXOptions with decreasing implied volatility
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use